NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2025)
Historic Profit After Tax for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's Profit After Tax fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
- Latest data reveals that NewAmsterdam Pharma reported Profit After Tax of -$72.0 million as of Q3 2025, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Profit After Tax high stood at -$16.6 million for Q3 2024, and its period low was -$93.8 million during Q1 2024.
- Its 3-year average for Profit After Tax is -$49.8 million, with a median of -$42.0 million in 2023.
- As far as peak fluctuations go, NewAmsterdam Pharma's Profit After Tax skyrocketed by 6468.08% in 2024, and later plummeted by 33254.04% in 2025.
- NewAmsterdam Pharma's Profit After Tax (Quarter) stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its last three reported values are -$72.0 million in Q3 2025, -$17.4 million for Q2 2025, and -$39.5 million during Q1 2025.